Skip to main content
Premium Trial:

Request an Annual Quote

Proteostasis Therapeutics Licenses GeneGo's MetaCore

NEW YORK (GenomeWeb News) –GeneGo said today that Proteostasis Therapeutics has licensed its MetaCore curated data mining and analysis platform.

Proteostasis Therapeutics is developing small molecule therapeutics based on studies of the human proteostasis network, the balance of proteins that can protect the body from diseases, GeneGo said. Deficiencies in that network can lead to a range of diseases, such as emphysema, type II diabetes, Alzheimer's disease, and Huntington's disease, said GeneGo.

St. Joseph, Mich.-based GeneGo is developing pathway reconstruction maps for a number of diseases, including neurodegenerative disorders.

Proteostasis Therapeutics will use MetaCore's curated database of protein interactions in its protein characterization-focused efforts to discover small molecules that could be used to treat diseases.

Financial terms of the agreement were not released.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.